Patterns of Duvelisib-Induced Lymphocytosis in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Those With High-Risk Factors Treated in the DUO Trial

Jacqueline Barrientos,1 Ian W. Flinn,2 Matthew S. Davids,3 Amanda Cashen,4 Nicholas Chiorazzi,5 Shih-Shen Chen,6 Samantha Hidy,7 Jonathan Pachter,8 Stephanie Lustgarten,9 David T. Weaver,10 Jennifer R. Brown2

1Cll Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, USA; 2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; 3Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 4Division of Medicine, Javits Outreach Center for Oncology, The Feinberg Institute for Medical Research, Northwell Health, Manhasset, NY, USA; 5Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 6Department of Oncology, Washington University Medical School, St Louis, MO, USA; 7Keeping Cancer at Bay, San Diego, CA, USA; 8Beacon Medical Group, Edmonton, AB, Canada; 9Freenome, Inc., Cambridge, MA, USA; 10Department of Medical Oncology and Center for Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA, USA.

CONCLUSIONS

• DUO therapy induced rapid lymphocytosis that occurred within 1 week of treatment in patients with R/R-CLL/SLL.
• Lymphocytosis was transient and resolved after approximately 14 weeks.
• DUO-related lymphocytosis was concurrent with an accompanying reduction in lymphopenia.
• DUO, a dual PI3K-γ/δ inhibitor, resulted in a >50% reduction in BL ALC in preclinical studies, dual PI3K-γ/δ inhibition was more effective than PI3K-δ inhibition in reducing CLL cell burden.
• Similar patterns of lymphocytosis were observed in patients regardless of poor prognostic indicators and were not correlated with worse outcomes.

REFERENCES


ACKNOWLEDGMENTS

Invested or holding stock: Kyle Cudney, PhD, of P377 Synthesis Communications Inc., and funded by专卖店Foundation.

Selected copies of Resolved DUO (n = 14) or OFA (n = 15) in a subset of patients with R/R-CLL/SLL, including those with high-risk factors.

Figure 3. Patients With Prolonged Lymphocytosis Have a Similar PFS to DUO-Treated Patients Without Prolonged Lymphocytosis

Figure 1. DUV Dau Delt of PI3K-δ, Mechanism of Action

Figure 2. DUV Significantly Improved PFS in R/R-CLL/SLL Patients

Table 3. Median Change From Baseline ALC and LMR

Table 4. Lymphocytosis in High-Risk Patients With R/R-CLL/SLL Receiving DUV

Table 5. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 6. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 7. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 8. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 9. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 10. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Figure 4. Median Change From BL in ALC and Lymph Node SPD Over Time With DUV

Figure 5. HZM Significantly Reduced the Number of CLL B Cells in the Spleen of a CLL PDX Model

REFERENCES


ACKNOWLEDGMENTS

Invested or holding stock: Kyle Cudney, PhD, of P377 Synthesis Communications Inc., and funded by专卖店Foundation.

Selected copies of Resolved DUO (n = 14) or OFA (n = 15) in a subset of patients with R/R-CLL/SLL, including those with high-risk factors.

Figure 3. Patients With Prolonged Lymphocytosis Have a Similar PFS to DUO-Treated Patients Without Prolonged Lymphocytosis

Figure 1. DUV Dau Delt of PI3K-δ, Mechanism of Action

Figure 2. DUV Significantly Improved PFS in R/R-CLL/SLL Patients

Table 3. Median Change From Baseline ALC and LMR

Table 4. Lymphocytosis in High-Risk Patients With R/R-CLL/SLL Receiving DUV

Table 5. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 6. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 7. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 8. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 9. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Table 10. Summary of Lymphocytosis in Patients With R/R-CLL/SLL Receiving DUV

Figure 4. Median Change From BL in ALC and Lymph Node SPD Over Time With DUV

Figure 5. HZM Significantly Reduced the Number of CLL B Cells in the Spleen of a CLL PDX Model

REFERENCES


ACKNOWLEDGMENTS

Invested or holding stock: Kyle Cudney, PhD, of P377 Synthesis Communications Inc., and funded by专卖店Foundation.